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Abstract 
Background: Sleep abnormalities are common in schizophrenia, often 
appearing before psychosis onset; however, the mechanisms for this are 
uncertain. We investigated whether genetic risk for schizophrenia is 
associated with sleep phenotypes. 
Methods: We used data from 6,058 children and 2,302 mothers from the 
Avon Longitudinal Study of Parents and Children (ALSPAC). We examined 
associations between a polygenic risk score for schizophrenia and sleep 
duration in both children and mothers, and nightmares in children, along with 
genetic covariances between these traits.  
Results: Polygenic risk for schizophrenia was associated with increased risk 
of nightmares (OR=1.07, 95% CI: 1.01 – 1.14, p=0.02) in children, and also 
with less sleep (β=-44.52, 95% CI: -88.98, -0.07; p=0.05). We observed a 
similar relationship with sleep duration in mothers, although evidence was 
much weaker (p=0.38). Finally, we found evidence of genetic covariance 
between schizophrenia risk and reduced sleep duration in children and 
mothers, and between schizophrenia risk and nightmares in children.  
Conclusions: These molecular genetic results support recent findings from 
twin analysis that show genetic overlap between sleep disturbances and 
psychotic-like experiences. They also show, for the first time, a genetic 
correlation between schizophrenia liability and risk of nightmares in childhood. 
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1. Introduction 
Sleep disturbance is very common in psychotic disorders such as 
schizophrenia. For example, a meta-analysis of observational studies showed 
that sleep efficiency and total sleep time are diminished in schizophrenia, 
whilst sleep latency is increased, independent of medications [1]. These 
findings are supported by polysomnography studies [2]. Similarly, sleep 
dysfunction is more common in individuals at ultra-high-risk for psychosis [3], 
and is associated with higher risk of incident psychotic experiences [4], 
paranoid thinking [5] and hallucinatory experiences [6] in population-based 
cohort studies.  
A recent report from the Twins Early Development Study (TEDS) 
demonstrated that psychotic-like experiences and sleep disturbances in 
adolescence share genetic influences [7]. Using data from 4,800 pairs of 
twins, they found a mean genetic correlation of 0.54 between self-reported 
paranoia, hallucinations and cognitive disorganisation, and self-reported sleep 
quality and insomnia. Bivariate heritability analyses showed that shared 
genetic influences accounted for on average 65% of the phenotypic 
correlation between phenotypes. This genetic relationship could be explained 
in several ways. For example, genetic variants could independently influence 
sleep and psychotic-like experiences, both sleep and psychotic-like 
experiences could be affected by a shared genetically influenced process, or 
there could be a causal relationship between sleep and psychotic-like 
experiences. We aimed to build on these analyses by using a polygenic risk 
score derived from the largest genome-wide association study (GWAS) of 
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schizophrenia to date [8] to investigate the genetic relationship between 
schizophrenia liability, sleep duration and childhood nightmares through two 
complimentary approaches.  
First, we examined whether genetic risk for schizophrenia is associated with 
sleep dysfunction during childhood and adulthood in the population-based 
Avon Longitudinal Study of Parents and Children (ALSPAC). We did this by 
combining information from the Psychiatric Genomics Consortium (PGC) 
GWAS into a polygenic risk score that indexes cumulative genetic risk for 
schizophrenia. The PGC report a variance explained in schizophrenia by the 
polygenic risk score at a p-value threshold of 0.05 of 7% [8]. This approach 
has previously shown that genetic risk for schizophrenia is associated with 
phenotypes such as cognitive deficits [9,10], anxiety and negative symptoms 
[11] during childhood and adolescence. 
Second, we assessed the genetic covariance between schizophrenia and 
sleep measures in childhood and adulthood using polygenic risk score data to 
estimate the average genome-wide relationship between these phenotypes.  
 6 
2. Methods 
2.1. Cohort description 
ALSPAC is a prospective birth cohort study which initially recruited 14,541 
pregnant women living in the Bristol area in the UK, with an expected delivery 
date from 1st April 1991 to the 31st December 1992 [12]. 14, 676 fetuses were 
included in the initial ALSPAC sample, with 14,062 live births and, of these, 
13,988 were alive after 1 year. At 7 years of age further recruitment occurred, 
resulting in a total sample size for analyses of 15, 458, with 14,755 live births 
and 14,701 alive at 1 year. Data has been collected on mothers and their 
offspring via questionnaires, clinic visits and other forms of information.  The 
ALSPAC sample is generally representative of the UK population of the same 
age, although, like many other cohorts, there is over-representation of more 
affluent groups (6.22% with low household income, as indicated by free 
school meals, in ALSPAC compared to 12.49% in the National Pupil 
Database) and under-representation of non-White minority ethnic groups 
(96.09% White ethnicity in ALSPAC compared to 86.50% in the National Pupil 
Database) [12]. However, to avoid false positive results from population 
stratification, our analyses included only those with European ancestry. We 
also excluded those without both the genetic and the phenotypic data 
required, leaving between 5,121 and 6,058 children and 2,302 mothers in 
each analysis. Table 1 summarises the number of individuals with data 
available for each of the outcome measures. Including all the time points 
examined for sleep duration, there were a total of 28,138 data points. 
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Further details of ALSPAC can be found through the searchable data 
dictionary (http://www.bristol.ac.uk/alspac/researchers/access/). Ethical 
approval for the study was obtained from the ALSPAC Ethics and Law 
Committee and the local Research Ethics Committees. 
2.2. Phenotypic measures 
2.2.1. Sleep duration 
Information about sleep duration in children was obtained from parent-
completed questionnaire data collected at the ages of 4, 5, 6, 9 and 11 years. 
Sleep duration was calculated as the difference between reported time that 
the child went to sleep and time they awoke on weekdays.  
Sleep duration in the mothers was assessed through questionnaire data 
collected when they were on average 40.78 years old (SD=4.52). Participants 
were asked how many hours and minutes they slept for on work days on 
average in the last year. 
2.2.2. Nightmares 
The presence of nightmares was assessed through semi-structured interviews 
with participants at around the age of 12 and a half years [4,13]. Briefly, 
children were asked questions about nightmares, night terrors and 
sleepwalking since their 12th birthday, such as “Since your 12th birthday have 
you had any dreams that woke you up? Were they frightening?”. Positive 
responses were followed by further questions to distinguish between 
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nightmares and night terrors. These were then rated as present, suspected or 
absent. In this study we use data on nightmares only as this was associated 
with psychotic experiences in a previous study [13] and we wanted to 
examine whether this extended to genetic risk for schizophrenia. 
2.2.3. Covariates 
We used the child’s sex and age as covariates in the analyses of children’s 
sleep outcomes. We included mother’s age as a covariate in the analyses of 
mother’s sleep duration. 
2.3. Genetic data 
Genetic data for children and mothers was collected in the form of blood 
samples during clinic visits. Genotyping for children was conducted using the 
Illumina HumanHap 550quad chip and data was generated by Sample 
Logistics and Genotyping Facilities at the Wellcome Trust Sanger Institute 
and LabCorp (Laboratory Corporation of America) using support from 
23andMe. ALSPAC mothers were genotyped using the Illumina human660W-
quad array at Centre National de Génotypage (CNG) and genotypes were 
called with Illumina GenomeStudio. 
Quality control measures were conducted, and SNPs were excluded based on 
missingness, Hardy-Weinberg equilibrium P value and minor allele frequency. 
Samples were excluded based on gender mismatches, indeterminate X 
chromosome, minimal or excessive heterozygosity, disproportionate 
missingness, insufficient sample replication and evidence of population 
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stratification.  9,115 children and 500,527 SNPs passed the filters and data 
was imputed with a phased version of the 1000genomes reference panel from 
the Impute2 reference data repository. 9,048 mothers and 526,688 SNPs 
passed the filters and data was imputed using Impute V2.2.2 against the 
reference panel (all polymorphic SNPs excluding singletons), using all 2186 
reference haplotypes (including non-Europeans). After these procedures, 
removing participants with cryptic relatedness >5% and those who had 
withdrawn consent, there were 8,252 children and 8,252 mothers with 
genotype data available. 
2.4. Polygenic risk score construction 
We constructed polygenic risk scores using Plink version 1.9 [14] for each 
individual using summary statistics from the PGC schizophrenia GWAS [8]. 
SNPs with an imputation quality score greater than 0.9 and which were 
available in ALSPAC were clumped for linkage disequilibrium (LD), using an 
R2 of 0.25. We generated weighted polygenic risk scores by summing the 
number of risk alleles present for each SNP (0,1 or 2) weighted by the 
logarithm of its discovery sample odds ratio (OR). For estimating covariance 
(see below) we constructed twelve polygenic risk scores based on different 
thresholds of the schizophrenia GWAS p-values (0.5 to 1x10-7). The score 
constructed with a p-value threshold (pT) of 0.05 captured the most variance 
in genetic liability for schizophrenia in the PGC sub-datasets [8], so we used 
this as our primary exposure, with the remainder reported in Supplementary 
Table 1 and Supplementary Figure 1 in S1 File. Polygenic risk scores were z-
standardised, so effect sizes are given per standard deviation (SD) increase 
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in polygenic risk score. See section 3 of the supplementary methods in S1 
File for further details. 
2.5. Statistical analysis 
2.5.1. Association between polygenic risk score and sleep phenotypes  
We conducted statistical analyses in R version 3.2.2 (R Core Team, 2016) 
and Stata version 14.2 [16]. First, we investigated the association between the 
polygenic risk score for schizophrenia liability and sleep duration in childhood, 
by combining all time points into one stacked dataset. We used a linear 
mixed-effects model, with age nested within family ID as a random effect and 
covariates age, age2 and sex. We tested for an association between the 
polygenic risk score for schizophrenia liability and nightmares using an ordinal 
model with sex as a covariate. We tested the association between the 
polygenic risk score for schizophrenia liability and sleep duration in mothers 
using a linear model with age as a covariate. To estimate the variance 
explained by the schizophrenia polygenic risk score at pT 0.05 for each 
outcome we obtained r-squared values from models without covariates; an 
adjusted r-squared was obtained from the linear model, a pseudo r-squared 
was obtained from the ordinal model and a marginal r-squared (the proportion 
of variance explained by the fixed factors) was obtained for the linear mixed-
effects model.  
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2.5.2 Estimating genetic covariance between schizophrenia liability and sleep 
phenotypes in childhood and adulthood 
Because individual level data were available for the sleep phenotypes and 
summary data were available for the schizophrenia phenotype, we used the 
Additive Variance Explained and Number of Genetic Effects Method of 
Estimation (AVENGEME) [17] to estimate the genetic covariance between 
schizophrenia liability and sleep duration and schizophrenia liability and 
nightmares in children, and between schizophrenia liability and sleep duration 
in mothers. To estimate a genetic model AVENGEME used the T-scores from 
results of the association between a series of polygenic risk scores at different 
discovery sample thresholds and the outcomes, sample sizes from the 
training and test samples, the number of variants used to create the scores, 
the p-value thresholds used to create the scores and the population 
prevalence of schizophrenia (we used 0.04) and case/control sampling 
fractions for the PGC data (0.43). Using this information, the approach is able 
to estimate the variance explained by genetic effects in the training sample, 
the variance explained by the polygenic risk score in the outcomes in 
ALSPAC, the genetic covariance between the training and target samples and 
the proportion of null SNPs with no effect on the trait in the training sample. 
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3. Results 
3.1 Association between polygenic risk of schizophrenia and sleep 
phenotypes 
3.1.1. Sleep duration in children 
We found that a 1SD increase in the schizophrenia polygenic risk score was 
associated with a decrease in sleep duration of 44.52 seconds (95% CI: -
88.98, -0.07; p=0.05) (Table 2). This was consistent across other polygenic 
risk score thresholds (pT 0.01 – 0.5) (Supplementary Table 1 and 
Supplementary Figure 1 in S1 File). Examining sleep duration at different 
ages indicates that the effect size increases after age 5 (Supplementary Table 
2 in S1 File), although there was little evidence of an interaction between 
polygenic risk and age when an interaction term was added to the mixed-
effects model (p=0.23). 
3.1.2. Nightmares in children 
We found evidence of increased risk of nightmares in those with greater 
polygenic risk (OR=1.07; 95% CI: 1.01, 1.14; p=0.02) (Table 2). We found a 
similar pattern for other polygenic risk score thresholds (0.05 – 0.5) 
(Supplementary Table 4 and Supplementary Figure 2 in S1 File). We found no 
evidence that the proportional odds assumption was violated (p=0.89).  
Adjusting for the mothers’ polygenic risk score in the analyses for sleep 
duration and nightmares in children had minimal effect (Supplementary 
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Tables 3 and 5 in S1 File), indicating that the association is not confounded by 
the mother’s psychopathology. 
3.1.3. Sleep duration in mothers 
The effect size of the association between schizophrenia polygenic risk score 
and sleep duration in mothers was similar to that seen in children, although 
evidence in support of this association was extremely weak (β=-57.90 
seconds; 95% CI: -186.57, 70.76; p=0.38) (Table 2), most likely because the 
smaller sample size in the mothers’ cohort led to lower power and less precise 
estimates. The results in mothers for other polygenic risk score thresholds can 
be seen in Supplementary Table 6 and Supplementary Figure 3 in S1 File, 
where scores calculated at more stringent p-value thresholds showed small 
positive associations (0.01 to 1x10-7) compared with small negative 
associations for pT 0.5 to 0.01.  
3.2. Genetic overlap between sleep phenotypes and schizophrenia risk 
In the ALSPAC children, our AVENGEME analyses indicate a positive 
covariance between nightmares and genetic liability for schizophrenia 
(covariance= 0.07, 95% CI: 0.05, 0.10). We found a negative covariance 
between sleep duration and genetic liability for schizophrenia in children 
(covariance= -0.008, 95% CI: -0.20, -0.003) and between sleep duration and 
genetic liability for schizophrenia in mothers (covariance= -0.04, 95% CI: -
0.07, -0.01) (see Supplementary Table 7 in S1 File for full results).
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4. Discussion 
We investigated whether genetic risk for schizophrenia is associated with 
sleep outcomes during childhood and adulthood. Our results demonstrate, for 
the first time with molecular genetic data, that greater polygenic risk for 
schizophrenia is associated with shorter sleep duration, and we report a new 
association between greater polygenic risk of schizophrenia and increased 
risk of nightmares in early life.  
These results build on previous twin study findings of shared genetic effects 
between schizophrenia and disrupted sleep [7] by showing that the 
association extends to collections of known and measured DNA variants 
identified through recent well-powered GWAS studies. 
The effect size of schizophrenia genetic risk on sleep duration in childhood in 
this study is small, equating to only a few minutes of sleep difference between 
individuals scoring three standard deviations above, compared to individuals 
scoring three standard deviations below the mean for polygenic risk. This is 
likely to reflect both measurement error in the parent-reported outcome 
measures, measurement error in the estimation of the effect sizes of the 
individual DNA variants that make up the polygenic score, and the fact that 
the pool of variants for the polygenic score is itself an incomplete set of 
human genomic variation, where many of the variants are imperfect proxies 
for true causal variants. Because of this, it seems likely that this small effect 
size is indicative of the stronger polygenic association reported by twin 
studies. Similarly, although we have reported results for sleep duration, we 
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have no direct measure of sleep quality, so the marginally lower duration of 
sleep may index greater disruption in sleep architecture that could have 
important effects on psychopathology. The R2 for sleep duration indicates that 
the schizophrenia polygenic risk score explains 0.02% of the variation in 
sleep. To put this into context, the PGC article reports that 7% of the variation 
in schizophrenia is explained by the polygenic risk score [8]. In cross-disorder 
analyses, the schizophrenia polygenic risk score explains smaller amounts of 
variation ranging from 0. 08% for autism spectrum disorder to 2.3% for bipolar 
disorder [18], with similarly low variance explained for cognition (<1%) [10]. 
Therefore, whilst we find a small amount of variation explained in sleep 
duration, this is on a similar scale to other cross-disorder analyses. 
We were, however, able to combine measures of sleep duration from several 
different ages, which is likely to have reduced error that was not shared 
across measurement occasions. In addition, the data we used were from a 
population-based sample that is less likely to be subject to some of the biases 
associated with ascertainment of clinical samples. 
Whilst these findings provide evidence of some underlying shared genetic 
mechanism between sleep phenotypes and schizophrenia, they do not allow 
us to determine the reason behind these associations. They could be due to 
pleiotropy, the phenotypes lying on a causal pathway, population stratification 
(although this is less likely due to restriction to those with a European 
ancestry) or a third unknown variable that causes both outcomes, where the 
PGC schizophrenia GWAS may have an ascertainment bias based on 
recruitment of those who had experienced this third variable. 
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Recent studies indicate that there may be a causal relationship. For example, 
a trial of cognitive-behavioural therapy for insomnia in people with psychosis 
reported a decrease in persecutory delusions, hallucinations, anxiety and 
depression [19], suggesting a causal effect of sleep dysfunction on 
psychopathology post-onset of psychosis. However, another study reported 
more mixed results with psychosis symptoms [20], and effects of sleep 
disturbance on incidence of psychosis might differ from those on illness 
severity. Randomised control trials that examine the impact of sleep 
interventions on psychosis incidence are not feasible given the incidence rate 
of psychotic disorders. Our results seem to mostly suggest the direction 
described in the first study, where disturbed sleep may result in increased risk 
for schizophrenia as our study finds associations with disturbed sleep in 
childhood and adolescence prior to any disorder and the association is with 
schizophrenia risk. However, it is possible that the reverse direction could be 
true if schizophrenia risk results in sub-clinical symptoms that cause disturbed 
sleep. There could also be a bi-directional causal association present or no 
causal association at all. Future well-powered analyses using techniques such 
as Mendelian Randomisation will be useful for examining whether 
relationships are causal and the direction of causality. 
Conclusion 
Our results use molecular data to support and extend the findings from twin 
studies of an overlap of genetic influences on sleep phenotypes and 
schizophrenia. We have presented novel findings with our use of polygenic 
risk scores that specifically relate to liability for schizophrenia risk, as opposed 
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to psychotic experiences. In addition, we found a novel relationship of shared 
genetic influences between schizophrenia and nightmares in children.
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Data availability 
The ALSPAC data management plan 
(http://www.bristol.ac.uk/alspac/researchers/data-access/documents/alspac-
data-management-plan.pdf) describes in detail the policy regarding data 
sharing, which is through a system of managed open access. The steps 
below highlight how to apply for access to the data included in this paper and 
all other ALSPAC data. The datasets used in this analysis are linked to 
ALSPAC project number B2172; please quote this project number during your 
application. 
1. Please read the ALSPAC access policy (PDF, 627kB) which describes the 
process of accessing the data and samples in detail, and outlines the costs 
associated with doing so. 
2. You may also find it useful to browse the fully searchable ALSPAC 
research proposals database, which lists all research projects that have been 
approved since April 2011. 
3. Please submit your research proposal for consideration by the ALSPAC 
Executive Committee. You will receive a response within 10 working days to 
advise you whether your proposal has been approved. 
If you have any questions about accessing data, please email alspac-
data@bristol.ac.uk. 
Consent 
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Written informed consent was obtained from participants or parents of 
participants, for children. Children were invited to give assent where 
appropriate. Study members have the right to withdraw their consent for 
elements of the study or from the study entirely at any time. Full details of the 
ALSPAC consent procedures are available on the study website 
(http://www.bristol.ac.uk/alspac/researchers/research-ethics/).  
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Table 1. Number of genotyped participants with each outcome measure 
Age Outcome 
measure 
N1 Percentage 
female 
Children 
4 years 9 months Sleep duration 6058 48.6% 
5 years 9 months Sleep duration 5641 48.9% 
6 years 9 months Sleep duration 5534 48.9% 
9 years 7 months Sleep duration 5735 49.4% 
11 years 8 
months 
Sleep duration 5170 50.2% 
12 years Nightmares 5121 51.1% 
Mothers 
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Average age of 
40 years 9 
months 
Sleep duration 2302 100% 
1The number of participants with both phenotype and genotype data available  
Table 2. Associations between schizophrenia polygenic risk (pT 0.05) and 
sleep outcomes 
Sleep phenotype (units) Beta or 
OR 
95% CI R-
squared1 
P-
value 
Sleep duration in children 
(seconds) 
-44.52 -88.98, -0.07 0.0002 0.05 
Nightmares in children 
(ordinal, OR) 
1.08 1.01, 1.14 0.001 0.02 
Sleep duration in mothers 
(seconds) 
-57.90 -186.59, 
70.76 
0.00004 0.34 
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1The r-squared values were a marginal r-squared (the proportion of variance explained by the 
fixed effects) for sleep duration in children, Nagelkerke’s pseudo r-squared for nightmares 
and the adjusted r-squared for sleep duration in mothers. 
 
Supplementary Material 
Supplementary Table 1. Associations between standardised 
schizophrenia polygenic risk score and sleep duration in children in 
ALSPAC. 
Risk score p-
value threshold 
Number 
of SNPs 
used 
Effect size 
of 
association 
(hours per 
SD) 
95% confidence 
intervals 
P-value 
0.5 191,361 -0.014 -0.026, -0.002 0.028 
0.4 169,908 -0.013 -0.025, -0.001 0.032 
0.3 143,909 -0.013 -0.025, -0.001 0.033 
0.2 112,635 -0.014 -0.026, -0.002 0.022 
0.1 73,598 -0.013 -0.025, -0.001 0.038 
0.05 47,960 -0.012 -0.024, -0.0002 0.048 
0.01 18,545 -0.014 -0.026, -0.002 0.022 
0.001 5,229 -0.011 -0.023, -0.0008 0.084 
0.0001 1,826 -0.005 -0.017, 0.007 0.402 
0.00001 737 -0.006 -0.018, 0.006 0.305 
0.000001 334 -0.003 -0.01, 0.009 0.644 
0.0000001 169 -0.002 -0.014, 0.010 0.745 
ALSPAC= Avon Longitudinal Study of Parents and Children 
 
 
Supplementary Table 2. Results from linear regressions for sleep duration 
and polygenic risk score for schizophrenia at each of five time points in 
childhood in ALSPAC.  
 
Effect size of association (hours 
per SD) 
95% CI P-
value 
4 yrs and 
9m 
-0.008 -0.026, 
0.010 
0.365 
5 yrs and 
9m 
-0.008 -0.026, 
0.010 
0.415 
6 yrs and 
9m 
-0.021 -0.039, -
0.003 
0.019 
9 yrs and 
7m 
-0.022 -0.040, -
0.004 
0.012 
11 yrs and 
8m 
-0.016 -0.036, 
0.004 
0.106 
The results shown are for the polygenic risk score constructed at the p<0.05 
threshold (47,960 SNPs). 
ALSPAC= Avon Longitudinal Study of Parents and Children 
Supplementary Table 3. Associations between standardised schizophrenia 
polygenic risk score and nightmares in children in ALSPAC. 
Risk score p-
value threshold 
Number of 
SNPs used 
Odds Ratio 
of 
association 
(per SD)1 
95% 
confidence 
intervals 
P-value 
0.5 191,361 1.104 1.037, 1.175 0.002 
0.4 169,908 1.102 1.035, 1.173 0.002 
0.3 143,909 1.108 1.041, 1.179 0.001 
0.2 112,635 1.108 1.041, 1.179 0.001 
0.1 73,598 1.098 1.032, 1.169 0.003 
0.05 47,960 1.075 1.010, 1.144 0.024 
0.01 18,545 1.051 0.988, 1.119 0.117 
0.001 5,229 1.025 0.963, 1.092 0.434 
0.0001 1,826 1.004 0.942, 1.069 0.910 
0.00001 737 0.982 0.922, 1.046 0.577 
0.000001 334 1.035 0.971, 1.102 0.290 
0.0000001 169 1.008 0.946, 1.074 0.812 
1The odds of the presence of nightmares, compared to suspected nightmares 
or absence of nightmares 
ALSPAC= Avon Longitudinal Study of Parents and Children 
Supplementary Table 4. Associations between standardised schizophrenia 
polygenic risk score and sleep duration in children in ALSPAC, whilst 
adjusting for mother’s polygenic risk at the same threshold. 
Risk 
score p-
value 
threshold 
Number 
of 
SNPs 
used 
Effect size of 
association 
(hours per 
SD) 
95% CI P-
value 
0.5 191,361 -0.012 -0.038, 0.014 0.367 
0.4 169,908 -0.011 -0.037, 0.015 0.421 
0.3 143,909 -0.011 -0.037, 0.015 0.406 
0.2 112,635 -0.013 -0.039, 0.013 0.336 
0.1 73,598 -0.021 -0.047, 0.005 0.113 
0.05 47,960 -0.018 -0.044, 0.008 0.180 
0.01 18,545 -0.022 -0.048, 0.004 0.099 
0.001 5,229 -0.015 -0.041, 0.011 0.259 
0.0001 1,826 -0.017 -0.043, 0.009 0.205 
0.00001 737 -0.011 -0.038, 0.015 0.408 
0.000001 334 -0.003 -0.029, 0.023 0.847 
0.0000001 169 -0.005 -0.031, 0.021 0.688 
ALSPAC= Avon Longitudinal Study of Parents and Children 
Supplementary Table 5. Associations between standardised schizophrenia 
polygenic risk score and nightmares in children in ALSPAC, whilst adjusting 
for mother’s schizophrenia polygenic risk score at the same threshold. 
Risk 
score p-
value 
threshold 
Number of 
SNPs used 
Odds Ratio of 
association (per 
SD)1 
95% confidence 
intervals 
P-
value 
0.5 191,361 1.072 0.942, 1.220 0.291 
0.4 169,908 1.076 0.945, 1.225 0.267 
0.3 143,909 1.070 0.940, 1.218 0.304 
0.2 112,635 1.078 0.946, 1.229 0.258 
0.1 73,598 1.048 0.920, 1.193 0.483 
0.05 47,960 1.007 0.885, 1.146 0.912 
0.01 18,545 0.993 0.873, 1.131 0.922 
0.001 5,229 0.973 0.856, 1.105 0.673 
0.0001 1,826 0.925 0.812, 1.054 0.242 
0.00001 737 0.900 0.788, 1.028 0.120 
0.000001 334 0.969 0.851, 1.103 0.632 
0.0000001 169 0.983 0.865, 1.118 0.798 
ALSPAC= Avon Longitudinal Study of Parents and Children
Supplementary Table 6. Associations between schizophrenia polygenic risk 
score and sleep duration in mothers in ALSPAC. 
Risk score p-value 
threshold 
Number of 
SNPs used 
Beta 
(hours per 
SD) 
95% 
confidence 
intervals 
P-value 
0.5 191,361 -0.029 -0.064, 0.006 0.119 
0.4 169,908 -0.027 -0.062, 0.008 0.138 
0.3 143,909 -0.022 -0.057, 0.013 0.228 
0.2 112,635 -0.021 -0.056, 0.014 0.262 
0.1 73,598 -0.015 -0.050, 0.020 0.408 
0.05 47,960 -0.016 -0.051, 0.019 0.378 
0.01 18,545 0.0001 -0.035, 0.035 0.994 
0.001 5,229 0.022 -0.013, 0.057 0.22 
0.0001 1,826 0.022 -0.013, 0.057 0.233 
0.00001 737 0.022 -0.015, 0.059 0.238 
0.000001 334 0.021 -0.016, 0.058 0.271 
0.0000001 169 0.009 -0.026, 0.044 0.613 
ALSPAC= Avon Longitudinal Study of Parents and Children 
Supplementary Table 7.  Results from estimating a polygenic model using 
AVENGEME, with T-scores from the observational associations and the same 
12 thresholds used for the polygenic risk score construction. 
Sleep 
phenotype 
Proportion 
of trait 
variance 
explained 
(95% CI)1 
Covariance (95% 
CI) 
Proportion of null 
markers (95% CI)2 
Sleep 
duration in 
children 
0.33 (0.01, 
1.00) 
-0.008 (-0.20, -
0.003) 
0.99 (0.92, 1.00) 
Nightmares 
in children 
(ordinal) 
0.28 (0.002, 
1.00) 
0.07 (0.05, 0.10) 0.51 (0.48, 0.97) 
Sleep 
duration in 
mothers 
0.002 
(1.00x10-04, 
1.00) 
-0.04 (-0.07, -0.01) 1.43x10-06 (5.46x10-
07, 1.00) 
AVENGEME= Additive Variance Explained and Number of Genetic Effects 
Method of Estimation, CI= Confidence intervals 
1 The proportion of trait variance explained by genetic effects in the training 
sample. This is from the regression of the target trait on the polygenic scores 
2 The proportion of markers/variants with no effect on training trait 
Supplementary Figure 1. Associations between polygenic risk score for 
schizophrenia at 12 different p-value thresholds and sleep duration in children 
in ALSPAC.  
 
ALSPAC= Avon Longitudinal Study of Parents and Children, PRS= Polygenic 
Risk Score
Supplementary Figure 2. Associations between polygenic risk score for 
schizophrenia at 12 different p-value thresholds and nightmares in children in 
ALSPAC.  
 
ALSPAC= Avon Longitudinal Study of Parents and Children, PRS= Polygenic 
Risk Score 
Supplementary Figure 3. Associations between polygenic risk score for 
schizophrenia at 12 different p-value thresholds and sleep duration in mothers 
in ALSPAC. 
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Risk Score 
 
